An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
<b>Background and Aims:</b> Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has shown effectiveness in trials for Crohn’s disease (CD) and ulcerative colitis (UC). This study evaluates its real-world effectiveness an...
Saved in:
Main Authors: | Hongzhen Wu, Tingting Xie, Qiao Yu, Tao Su, Min Zhang, Luying Wu, Xiaoling Wang, Xiang Peng, Min Zhi, Jiayin Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/1/190 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
by: Ronghui Li, et al.
Published: (2025-01-01) -
Modern Approaches in the Morphological Diagnosis of Inflammatory Bowel Diseases
by: A. S. Tertychnyy, et al.
Published: (2022-08-01) -
The Influence of Physical Activity on Inflammatory Markers, Intestinal Microbiota Composition and Disease Activity in Inflammatory Bowel Disease
by: Paulina Jakubczyk, et al.
Published: (2025-01-01) -
Dual Biologic or Small Molecule Therapy in Pediatric Inflammatory Bowel Disease: A Single Center Experience
by: Cheng Guo, et al.
Published: (2025-01-01) -
Substantiation of application and estimation of efficacy of probiotics at inflammatory bowel diseases
by: Ye. A. Poluektova, et al.
Published: (2015-05-01)